Skip to content
n:ews
Back to feed

Novartis in the lead to acquire cancer drug developer MorphoSys 

Reuters exclusively reported that drug maker Novartis AG (NOVN.S) is in advanced talks to acquire MorphoSys AG (MORG.DE), a developer of cancer treatments that has a market value of 1.6 billion euros ($1.7 billion). 

The post Novartis in the lead to acquire cancer drug developer MorphoSys  appeared first on Reuters News Agency.